VHCP Management II as of Sept. 30, 2017
Portfolio Holdings for VHCP Management II
VHCP Management II holds 21 positions in its portfolio as reported in the September 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 27.7 | $100M | 1.0M | 96.73 | |
| Biohaven Pharmaceutical Holding | 16.8 | $61M | 1.7M | 36.55 | |
| Ascendis Pharma A S (ASND) | 13.0 | $47M | 1.3M | 36.25 | |
| Zogenix | 8.8 | $32M | 907k | 35.05 | |
| Dbv Technologies (DBVTF) | 6.2 | $22M | 374k | 59.86 | |
| BioCryst Pharmaceuticals (BCRX) | 4.6 | $17M | 3.2M | 5.24 | |
| Argenx Se (ARGX) | 4.0 | $15M | 647k | 22.37 | |
| Edge Therapeutics | 3.8 | $14M | 1.3M | 10.73 | |
| Obseva Sa | 3.1 | $11M | 1.4M | 8.14 | |
| Myokardia | 3.1 | $11M | 265k | 42.85 | |
| Ra Pharmaceuticals | 3.1 | $11M | 770k | 14.60 | |
| Anaptysbio Inc Common (ANAB) | 1.6 | $5.9M | 168k | 34.95 | |
| Bellerophon Therapeutics | 1.3 | $4.7M | 4.1M | 1.14 | |
| Akari Therapeutics | 0.7 | $2.6M | 426k | 6.14 | |
| Lipocine | 0.4 | $1.5M | 387k | 3.97 | |
| Kalvista Pharmaceuticals (KALV) | 0.4 | $1.5M | 222k | 6.73 | |
| Madrigal Pharmaceuticals (MDGL) | 0.4 | $1.3M | 30k | 44.97 | |
| ARCA biopharma | 0.3 | $1.2M | 1.1M | 1.15 | |
| Adverum Biotechnologies | 0.3 | $1.0M | 280k | 3.65 | |
| Ocera Therapeutics | 0.1 | $544k | 477k | 1.14 | |
| Axovant Sciences | 0.1 | $524k | 76k | 6.88 |
